Literature DB >> 33521898

Landmark Trials in the Surgical Management of Mesothelioma.

Taylor Kantor1, Elliot Wakeam2.   

Abstract

The treatment of mesothelioma has evolved slowly over the last 20 years. While surgery as a standalone treatment has fallen out of favor, the importance of multimodality treatment consisting of combinations of chemotherapy, radiotherapy, and surgery have become more common in operable, fit patients. In this review, we discuss trials in surgery, chemotherapy, and radiation that have shaped contemporary multimodality treatment of this difficult malignancy, and we touch on the new and emerging immunotherapeutic and targeted agents that may change the future treatment of this disease. We also review the multimodality treatment regimens, with particular attention to trimodality therapy and neoadjuvant hemithoracic radiation strategies.

Entities:  

Mesh:

Year:  2021        PMID: 33521898     DOI: 10.1245/s10434-021-09589-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  78 in total

1.  Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008.

Authors:  Vanya Delgermaa; Ken Takahashi; Eun-Kee Park; Giang Vinh Le; Toshiyuki Hara; Tom Sorahan
Journal:  Bull World Health Organ       Date:  2011-06-13       Impact factor: 9.408

2.  Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.

Authors:  Jan P van Meerbeeck; Rabab Gaafar; Christian Manegold; Rob J Van Klaveren; Eric A Van Marck; Mark Vincent; Catherine Legrand; Andrew Bottomley; Channa Debruyne; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

3.  Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma.

Authors:  Elizabeth H Baldini; William G Richards; Ritu R Gill; Brian M Goodman; Olivia K Winfrey; Hannah M Eisen; Raymond H Mak; Aileen B Chen; David E Kozono; Raphael Bueno; David J Sugarbaker
Journal:  J Thorac Cardiovasc Surg       Date:  2015-02-07       Impact factor: 5.209

4.  The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.

Authors:  Claudia Proto; Diego Signorelli; Sandra Mallone; Arsela Prelaj; Giuseppe Lo Russo; Martina Imbimbo; Giulia Galli; Roberto Ferrara; Monica Ganzinelli; Giovanni Leuzzi; Francesca Gabriella Greco; Giuseppina Calareso; Laura Botta; Gemma Gatta; Marina Garassino; Annalisa Trama
Journal:  Clin Lung Cancer       Date:  2019-06-26       Impact factor: 4.785

5.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Authors:  Nicholas J Vogelzang; James J Rusthoven; James Symanowski; Claude Denham; E Kaukel; Pierre Ruffie; Ulrich Gatzemeier; Michael Boyer; Salih Emri; Christian Manegold; Clet Niyikiza; Paolo Paoletti
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

6.  The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.

Authors:  David Rice; Kari Chansky; Anna Nowak; Harvey Pass; Hedy Kindler; Lynn Shemanski; Isabelle Opitz; Sergi Call; Seiki Hasegawa; Kemp Kernstine; Cansel Atinkaya; Federico Rea; Philippe Nafteux; Valerie W Rusch
Journal:  J Thorac Oncol       Date:  2016-09-26       Impact factor: 15.609

7.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

8.  ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.

Authors:  Isabelle Opitz; Arnaud Scherpereel; Thierry Berghmans; Ioannis Psallidas; Markus Glatzer; David Rigau; Philippe Astoul; Servet Bölükbas; Jeanette Boyd; Johan Coolen; Charlotte De Bondt; Dirk De Ruysscher; Valerie Durieux; Corinne Faivre-Finn; Dean A Fennell; Francoise Galateau-Salle; Laurent Greillier; Mir Ali Hoda; Walter Klepetko; Aude Lacourt; Phil McElnay; Nick A Maskell; Luciano Mutti; Jean-Claude Pairon; Paul Van Schil; Jan P van Meerbeeck; David Waller; Walter Weder; Paul Martin Putora; Giuseppe Cardillo
Journal:  Eur J Cardiothorac Surg       Date:  2020-07-01       Impact factor: 4.191

9.  Malignant Mesothelioma Mortality - United States, 1999-2015.

Authors:  Jacek M Mazurek; Girija Syamlal; John M Wood; Scott A Hendricks; Ainsley Weston
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-03-03       Impact factor: 17.586

Review 10.  Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted/banned asbestos use.

Authors:  Naomi Alpert; Maaike van Gerwen; Emanuela Taioli
Journal:  Transl Lung Cancer Res       Date:  2020-02
View more
  2 in total

Review 1.  An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma.

Authors:  Alexander Davis; Helen Ke; Steven Kao; Nick Pavlakis
Journal:  Lung Cancer (Auckl)       Date:  2022-03-02

2.  Molecular Radiotherapy with 177Lu-Immunoliposomes Induces Cytotoxicity in Mesothelioma Cancer Stem Cells In Vitro.

Authors:  Tao Huang; Jae Sam Lee; Alexander L Klibanov; Jiang He
Journal:  Int J Mol Sci       Date:  2022-04-01       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.